Compare Stocks: RPTX, KYTX, CABA, and PRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$3.10 -1.0%	$2.88	$1.40 ▼ $4.23	$530.68M	3.3	3.99 million shs	3.11 million shs
KYTX Kyverna Therapeutics	$8.24 -2.1%	$8.15	$3.55 ▼ $13.67	$520.72M	1.93	768,420 shs	565,133 shs
PRTA Prothena	$9.39 -0.6%	$9.00	$7.73 ▼ $11.80	$494.74M	-0.29	466,172 shs	248,124 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	+13.82%	+16.36%	-14.25%	+93.21%
KYTX Kyverna Therapeutics	0.00%	+3.06%	+13.63%	-2.88%	+118.70%
PRTA Prothena	0.00%	+6.66%	+8.00%	-3.87%	+7.75%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+66.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$3.10 -1.0%	$2.88	$1.40 ▼ $4.23	$530.68M	3.3	3.99 million shs	3.11 million shs
KYTX Kyverna Therapeutics	$8.24 -2.1%	$8.15	$3.55 ▼ $13.67	$520.72M	1.93	768,420 shs	565,133 shs
PRTA Prothena	$9.39 -0.6%	$9.00	$7.73 ▼ $11.80	$494.74M	-0.29	466,172 shs	248,124 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	+13.82%	+16.36%	-14.25%	+93.21%
KYTX Kyverna Therapeutics	0.00%	+3.06%	+13.63%	-2.88%	+118.70%
PRTA Prothena	0.00%	+6.66%	+8.00%	-3.87%	+7.75%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+66.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	2.57	Moderate Buy	$15.33	394.62% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	264.08% Upside
PRTA Prothena	2.75	Moderate Buy	$23.75	152.93% Upside
RPTX Repare Therapeutics	2.00	Hold	$3.00	13.21% Upside

Current Analyst Ratings Breakdown

Latest RPTX, KYTX, CABA, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	PRTA Prothena	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
7/17/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/3/2026	CABA Cabaletta Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/3/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
PRTA Prothena	$9.68M	50.78	N/A	N/A	$5.21 per share	1.80
RPTX Repare Therapeutics	$11.87M	9.62	N/A	N/A	$3.56 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.33	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$1.69	N/A	N/A	N/A	N/A	-60.15%	-52.24%	N/A

Latest RPTX, KYTX, CABA, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	5.79	5.79
KYTX Kyverna Therapeutics	0.15	9.06	9.06
PRTA Prothena	N/A	25.05	25.05
RPTX Repare Therapeutics	N/A	10.71	10.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
KYTX Kyverna Therapeutics	18.08%
PRTA Prothena	97.08%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	6.44%
KYTX Kyverna Therapeutics	17.60%
PRTA Prothena	10.40%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	169.54 million	158.63 million	Optionable
KYTX Kyverna Therapeutics	96	61.84 million	50.96 million	Optionable
PRTA Prothena	130	52.35 million	46.91 million	Optionable
RPTX Repare Therapeutics	180	43.11 million	38.15 million	Optionable

RPTX, KYTX, CABA, and PRTA Headlines

Recent News About These Companies

Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million

July 27, 2026 | theglobeandmail.com

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | financialpost.comF

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | businesswire.com

Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M

December 25, 2025 | msn.com

Why Repare Therapeutics Inc.’s (RPTX) Stock Is Up 19.82%

December 25, 2025 | aaii.comA

RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug

December 24, 2025 | msn.com

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug

December 24, 2025 | ca.investing.com

Gilead to buy Repare Thera’s cancer candidate for up to $30M

December 24, 2025 | msn.com

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

December 24, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX, THS, RMBI Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025 | caledonianrecord.comC

Repare shareholders vote in favor of Xeno bid

November 22, 2025 | thepharmaletter.comT

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | financialpost.comF

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

November 18, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

November 17, 2025 | globenewswire.com

Repare Therapeutics downgraded to Hold from Buy at TD Cowen

November 17, 2025 | msn.com

Repare Therapeutics stock soars after acquisition deal with XenoTherapeutics

November 14, 2025 | za.investing.com

XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR

November 14, 2025 | msn.com

Repare Therapeutics enters into definitive agreement to be acquired by xenotherapeutics

November 14, 2025 | msn.com

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

November 14, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KYTX, CABA, and PRTA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$3.10 -0.03 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$3.16 +0.06 (+2.10%)

As of 07:02 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Kyverna Therapeutics NASDAQ:KYTX

$8.24 -0.18 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$8.23 -0.01 (-0.12%)

As of 06:44 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Prothena NASDAQ:PRTA

$9.39 -0.06 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$9.50 +0.11 (+1.16%)

As of 06:13 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Repare Therapeutics NASDAQ:RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, KYTX, CABA, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, KYTX, CABA, and PRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, KYTX, CABA, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KYTX, CABA, and PRTA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, KYTX, CABA, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, KYTX, CABA, and PRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, KYTX, CABA, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, KYTX, CABA, and PRTA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools